Tivantinib demonstrated antiproliferative activity in several human cancer cell lines that constitutively express MET (IC50 = 0.30 to 0.66 μM), and showed significant antitumor activity in multiple xenograft tumor mouse models [11]. The gene discussed is MET; the disease is neoplasm.